Bright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure

MT Newswires Live01-06

Bright Minds Biosciences (DRUG) said Tuesday its phase 2 study of BMB-101, to treat absence seizures and developmental and encephalopathic epilepsies, met the primary efficacy endpoint by showing a "robust" seizure reduction with a "favorable safety and tolerability" profile.

The trial enrolled a total of 24 participants and had a four-week baseline, four-week titration and maintenance period.

The company said the patients demonstrated a 73% median reduction in the number of absence seizure in the absence seizure group. It was also found to be "generally well tolerated" and there were no treatment-related serious adverse effects seen.

Bright Minds also said it has started preparations for global registrational trials in both absence seizures and developmental and encephalopathic epilepsies patients.

Shares of the company were up 28% in recent Tuesday premarket activity.

Price: 102.44, Change: +22.43, Percent Change: +28.03

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601890818?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601890818","market":"nz","top_or_hot":-1,"title":"Bright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/DRUG\">Bright Minds Biosciences</a> (DRUG) said Tuesday its phase 2 study of BMB-101, to treat absence seizures and developmental and encephalopathic epilepsies, met the primary efficacy endpoint by showing a \"robust\" seizure reduction with a \"favorable safety and tolerability\" profile.</p><p>The trial enrolled a total of 24 participants and had a four-week baseline, four-week titration and maintenance period.</p><p>The company said the patients demonstrated a 73% median reduction in the number of absence seizure in the absence seizure group. It was also found to be \"generally well tolerated\" and there were no treatment-related serious adverse effects seen.</p><p>Bright Minds also said it has started preparations for global registrational trials in both absence seizures and developmental and encephalopathic epilepsies patients.</p><p>Shares of the company were up 28% in recent Tuesday premarket activity.</p><p>Price: 102.44, Change: +22.43, Percent Change: +28.03</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-06 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/DRUG\">Bright Minds Biosciences</a> (DRUG) said Tuesday its phase 2 study of BMB-101, to treat absence seizures and developmental and encephalopathic epilepsies, met the primary efficacy endpoint by showing a \"robust\" seizure reduction with a \"favorable safety and tolerability\" profile.</p><p>The trial enrolled a total of 24 participants and had a four-week baseline, four-week titration and maintenance period.</p><p>The company said the patients demonstrated a 73% median reduction in the number of absence seizure in the absence seizure group. It was also found to be \"generally well tolerated\" and there were no treatment-related serious adverse effects seen.</p><p>Bright Minds also said it has started preparations for global registrational trials in both absence seizures and developmental and encephalopathic epilepsies patients.</p><p>Shares of the company were up 28% in recent Tuesday premarket activity.</p><p>Price: 102.44, Change: +22.43, Percent Change: +28.03</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DRUG.AU","symbol_name":"BETASHARES GLOBAL HEALTHCARE","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601890818","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601890818","pubTimestamp":1767705644,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bright Minds Biosciences  said Tuesday its phase 2 study of BMB-101, to treat absence seizures and developmental and encephalopathic epilepsies, met the primary efficacy endpoint by showing a \"robust\" seizure reduction with a \"favorable safety and tolerability\" profile.The trial enrolled a total of 24 participants and had a four-week baseline, four-week titration and maintenance period.The company said the patients demonstrated a 73% median reduction in the number of absence seizure in the absence seizure group. It was also found to be \"generally well tolerated\" and there were no treatment-related serious adverse effects seen.Bright Minds also said it has started preparations for global registrational trials in both absence seizures and developmental and encephalopathic epilepsies patients.Shares of the company were up 28% in recent Tuesday premarket activity.Price: 102.44, Change: +22.43, Percent Change: +28.03","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DRUG.AU":"BETASHARES GLOBAL HEALTHCARE","DRUG":"Bright Minds Biosciences Inc","BK4139":"生物科技"},"translate_title":"Bright Minds Biosciences表示BMB-101的2期试验结果显示癫痫发作“强劲”减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRUG":1,"DRUG.AU":1},"content_text":"Bright Minds Biosciences (DRUG) said Tuesday its phase 2 study of BMB-101, to treat absence seizures and developmental and encephalopathic epilepsies, met the primary efficacy endpoint by showing a \"robust\" seizure reduction with a \"favorable safety and tolerability\" profile.The trial enrolled a total of 24 participants and had a four-week baseline, four-week titration and maintenance period.The company said the patients demonstrated a 73% median reduction in the number of absence seizure in the absence seizure group. It was also found to be \"generally well tolerated\" and there were no treatment-related serious adverse effects seen.Bright Minds also said it has started preparations for global registrational trials in both absence seizures and developmental and encephalopathic epilepsies patients.Shares of the company were up 28% in recent Tuesday premarket activity.Price: 102.44, Change: +22.43, Percent Change: +28.03","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601890818","isCrawlerRequest":true}